This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Creates Novel Antibody-Cytokine Conjugates For Cancer Therapy

Cancers are generally believed to be derived from single cells that are genetically mutated, resulting in many divisions resulting in an expanding tumor that eventually spreads to local and distant organs. Cancer deaths usually are due to this metastasis affecting the new organs invaded. The initiating cells are often referred to as cancer stem cells. How these turn into heterogeneous populations of cancer cells within the original tumor and even in the metastases is the subject of intense recent research, which has also focused on the tumor's microenvironment and how cancer cells interact with their neighboring supportive cells.

In a separate poster presentation at the same AACR Annual Meeting, the Company reported that genes of human cancer jump into adjacent normal cells by fusion of both cells. This study was done in collaboration with researchers from the Garden State Cancer Center, Center for Molecular Medicine and Immunology in Morris Plains, NJ, and the Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, in Bethesda, MD.

This team of scientists discovered a transfer of human genes to normal hamster cells when cells from tissues involved by Hodgkin's lymphoma from two patients were implanted to hamsters. In all, 7 of 24 human genes tested were present in the malignant tumors growing in the hamsters for extended periods of 5 to 6 years, with evidence of metastasis in the hamsters within 21 days of the original grafting of the human tumors. By means of sensitive DNA coloring of the tumor cells, the investigators proved that human and hamster DNA were present in single cancer cells, representing fused cells of both species.

"These findings may explain how cancers develop and change with time, spreading by metastasis to other organs by overcoming immunity to the cancer cells and could lead to therapeutic strategies," commented the lead investigator, Dr. David M. Goldenberg, Chief Scientific Officer and Chief Medical Officer of Immunomedics, and President of the Center for Molecular Medicine and Immunology.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs